Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Although chimeric antigen receptor (CAR) T cell therapy represents a transformative
immunotherapy, it is also associated with distinct toxicities that contribute to morbidity and …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …

Abstract In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene
ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy …

In preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune
effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line
chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study …

The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

Background The identification of oncogenic mutations in diffuse large B-cell lymphoma
(DLBCL) has led to the development of drugs that target essential survival pathways, but …